XML 80 R66.htm IDEA: XBRL DOCUMENT
v2.4.1.9

14. Segment Reporting (Details) (USD $) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number Of Products And Services |  |  |  |  |  |  |  |  | 8,000 bio_NumberOfProductsAndServices |  |
Net sales | $ 598,200,000 us-gaap_SalesRevenueNet | $ 530,600,000 us-gaap_SalesRevenueNet | $ 536,800,000 us-gaap_SalesRevenueNet | $ 509,300,000 us-gaap_SalesRevenueNet | $ 602,600,000 us-gaap_SalesRevenueNet | $ 505,100,000 us-gaap_SalesRevenueNet | $ 525,300,000 us-gaap_SalesRevenueNet | $ 499,700,000 us-gaap_SalesRevenueNet | $ 2,175,044,000 us-gaap_SalesRevenueNet | $ 2,132,694,000 us-gaap_SalesRevenueNet | $ 2,069,235,000 us-gaap_SalesRevenueNet
Interest expense |  |  |  |  |  |  |  |  | 22,131,000 us-gaap_InterestExpense | 61,271,000 us-gaap_InterestExpense | 51,112,000 us-gaap_InterestExpense
Depreciation and amortization |  |  |  |  |  |  |  |  | 149,900,000 us-gaap_DepreciationDepletionAndAmortization | 147,200,000 us-gaap_DepreciationDepletionAndAmortization | 130,400,000 us-gaap_DepreciationDepletionAndAmortization
Segment profit |  |  |  |  |  |  |  |  | 149,984,000 us-gaap_OperatingIncomeLoss | 169,456,000 us-gaap_OperatingIncomeLoss | 264,176,000 us-gaap_OperatingIncomeLoss
Total assets | 3,341,278,000 us-gaap_Assets |  |  |  | 3,388,790,000 us-gaap_Assets |  |  |  | 3,341,278,000 us-gaap_Assets | 3,388,790,000 us-gaap_Assets |
Payments to Acquire Property, Plant, and Equipment |  |  |  |  |  |  |  |  | 120,999,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment | 106,658,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment | 142,869,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Life Science [Member] |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 728,300,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 710,000,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 688,400,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember
Interest expense |  |  |  |  |  |  |  |  | 5,500,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 10,400,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 13,400,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember
Depreciation and amortization |  |  |  |  |  |  |  |  | 33,200,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 32,600,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 26,300,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember
Segment profit |  |  |  |  |  |  |  |  | (14,700,000)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | (13,700,000)us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 13,200,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember
Total assets | 361,500,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember |  |  |  | 389,100,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember |  |  |  | 361,500,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 389,100,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember |
Payments to Acquire Property, Plant, and Equipment |  |  |  |  |  |  |  |  | 14,100,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember | 19,800,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = bio_LifeScienceMember |
Clinical Diagnostics [Member] |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 1,432,300,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 1,408,000,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 1,365,500,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember
Interest expense |  |  |  |  |  |  |  |  | 15,900,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 30,100,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 37,800,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember
Depreciation and amortization |  |  |  |  |  |  |  |  | 95,800,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 91,500,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 92,900,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember
Segment profit |  |  |  |  |  |  |  |  | 167,100,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 176,200,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 202,600,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember
Total assets | 884,900,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember |  |  |  | 980,900,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember |  |  |  | 884,900,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 980,900,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember |
Payments to Acquire Property, Plant, and Equipment |  |  |  |  |  |  |  |  | 60,100,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember | 66,500,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = bio_ClinicalDiagnosticsMember |
All Other Segments [Member] |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  | 14,400,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 14,700,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 15,300,000 us-gaap_SalesRevenueNet / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember
Interest expense |  |  |  |  |  |  |  |  | 100,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 100,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 200,000 us-gaap_InterestExpense / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember
Depreciation and amortization |  |  |  |  |  |  |  |  | 0 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 100,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 100,000 us-gaap_DepreciationDepletionAndAmortization / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember
Segment profit |  |  |  |  |  |  |  |  | 1,200,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 1,100,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 1,600,000 us-gaap_OperatingIncomeLoss / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember
Total assets | 4,800,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember |  |  |  | 5,100,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember |  |  |  | 4,800,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | 5,100,000 us-gaap_Assets / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember |
Payments to Acquire Property, Plant, and Equipment |  |  |  |  |  |  |  |  | $ 0 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember | $ 200,000 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment / us-gaap_StatementBusinessSegmentsAxis = us-gaap_AllOtherSegmentsMember |

X
- Definition Number Of Products And Services + References No definition available. + Details
Name: | bio_NumberOfProductsAndServices
Namespace Prefix: | bio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cost of borrowed funds accounted for as interest expense. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 + Details
Name: | us-gaap_InterestExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bio_ClinicalDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bio_LifeScienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |